Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine
Gwendoline Ragonnet, Elisabeth Jouve, Lionel Velly, Marc Leone, Gary Duclos, Jeremy Bourenne, Karim Harti Souab, Caroline Solas, Romain Guilhaumou
Future Pharmacology, doi:10.3390/futurepharmacol2010007
During the SARS-CoV-2 pandemic, hydroxychloroquine (HCQ), was among the first drugs to be tested due to demonstrated in vitro antiviral activity against SARS-CoV-2. Pharmacokinetic variability was expected due to the frequent comorbidities and pathophysiological modifications observed in severe COVID-19 patients hospitalized in intensive care units (ICUs). The aim of this study was to describe HCQ plasmatic concentrations in ICUs and assess variability factors. A multicentric retrospective study was carried in four ICUs in Marseille from March to April 2020. There were two dosing regimens: 400 mg after a 400 mg loading dose (DR1); and 600 mg without a loading dose (DR2). HCQ concentrations were determined every 2 or 3 days. The impacts of demo-graphic, biological, and clinical covariates were investigated. The median HCQ concentration was: 0.096 mg/L on day (D) 2, 0.129 mg/L on D3 to D5, 0.140 mg/L on D6 to D10 for DR1 versus 0.116 mg/L, 0.261 mg/L, and 0.30 mg/L, respectively, for DR2. At D2, 53.9% and 46.2% of patients with DR1 and DR2, respectively, presented HCQP concentrations <0.1 µg/mL and 48.2% versus 10.7% at D3 to D5. Time post-initiation, dosing regimen, nasogastric administration, and weight showed significant association with HCQ variability. The high proportion of suboptimal HCQ concentrations can be explained by a lack of optimized dosing regimen and numerous pathophysiological changes in the COVID-19/ICU population.
References
Abdul-Aziz, Alffenaar, Bassetti, Bracht, Dimopoulos et al., Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper, Intensive Care Med,
doi:10.1007/s00134-020-06050-1Abdulaziz, Shah, Mccune, Hydroxychloroquine: Balancing the need to maintain therapeutic levels with ocular safety: An update, Curr. Opin. Rheumatol,
doi:10.1097/BOR.0000000000000500Alarcón, Mcgwin, Bertoli, Fessler, Calvo-Alén et al., Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L), Ann. Rheum. Dis,
doi:10.1136/ard.2006.068676Cunha, Alexander, Ashby, Lee, Chusney et al., Hydroxycloroquine blood concentration in lupus nephritis: A determinant of disease outcome?, Nephrol. Dial. Transplant,
doi:10.1093/ndt/gfx318Doudka, Giocanti, Basso, Ugdonne, Barthelemy et al., Development and validation of a simple and rapid UHPLC-MS/MS method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic, Ther. Drug Monit,
doi:10.1097/FTD.0000000000000836Fan, Ma, Chen, Yang, Cheng et al., Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS, Rheumatol. Ther,
doi:10.1007/s40744-015-0012-0Gagnieu, Garraffo, Solas, Peytavin, Guilhaumou et al., Recommandations pour le Suivi Thérapeutique Pharmacologique du lopinavir/r et de l'hydroxychloroquine chez les patients traités pour une infection à SARS-CoV-2 (COVID-19
Gautier-Veyret, Truffot, Bailly, Fonrose, Thiebaut-Bertrand et al., Inflammation is a potential risk factor of voriconazole overdose in hematological patients, Fundam. Clin. Pharm,
doi:10.1111/fcp.12422Giaime, Guenoun, Pedinielli, Narbonne, Bergounioux et al., Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection, Nephrol. Dial. Transplant,
doi:10.1093/ndt/gfaa191Kivity, Landevitz, Shoenfeld, Ben-Zvi, Hydroxychloroquine: From malaria to autoimmunity, Clin. Rev. Allergy Immunol,
doi:10.1007/s12016-010-8243-xLagier, Million, Gautret, Colsona, Cortaredonaa et al., Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med. Infect. Dis,
doi:10.1016/j.tmaid.2020.101791Lê, Peiffer-Smadja, Guedj, Néant, Mentré et al., Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial, J. Antimicrob. Chemotherpy,
doi:10.1093/jac/dkaa191Mahévas, Tran, Roumier, Chabrol, Paule et al., Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: Observational comparative study using routine care data, Br. Med. J,
doi:10.1136/bmj.m1844Marzolini, Stader, Stoeckle, Franzeck, Egli et al., Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations, Antimicrob. Agents Chemother,
doi:10.1128/AAC.01177-20Morita, Takahashi, Yoshida, Yokota, Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus, Ther. Drug Monit,
doi:10.1097/FTD.0000000000000261Oberoi, Zhao, Sidhu, Viani, Trinh et al., A Phase 1 Study to Evaluate the Effect of Crushing, Cutting Into Half, or Grinding of Glecaprevir/Pibrentasvir Tablets on Exposures in Healthy Subjects, J. Pharm. Sci
Petri, Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibodypositive patients, Curr. Rheumatol. Rep,
doi:10.1007/s11926-010-0141-yRainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology,
doi:10.1007/s10787-015-0239-yRoustit, Guilhaumou, Molimard, Drici, Laporte et al., Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence, Therapies,
doi:10.1016/j.therap.2020.05.010Smit, Peeters, Van Den Anker, Knibbe, Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties, Clin. Pharmacokinet,
doi:10.1007/s40262-020-00891-1Thémans, Belkhir, Dauby, Yombi, De Greef et al., Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization, Eur. J. Drug Metab. Pharmacokinet,
doi:10.1007/s13318-020-00648-yVenisse, Peytavin, Bouchet, Gagnieu, Garrafo et al., Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection, Antivir. Res,
doi:10.1016/j.antiviral.2020.104866Wu, Chen, Cai, Xia, Xing et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern. Med,
doi:10.1001/jamainternmed.2020.0994Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am,
doi:10.1093/cid/ciaa237Yasu, Konuma, Kato, Kurokawa, Takahashi et al., Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients, Leuk. Lymphoma,
doi:10.1080/10428194.2017.1300897Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet
